转铁蛋白受体单克隆抗体纳米载药系统在白血病靶向治疗中的应用研究  

Application of transferrin receptor monoclonal antibody nanocarrier system in targeted therapy of leukemia

作　　者：韩海娜 王敏阁 HAN Haina;WANG Minge(Hematology Department,the First People's Hospital of Shangqiu City,Shangqiu,Henan 476000,China)

机构地区：[1]商丘市第一人民医院血液内科,河南商丘476000

出　　处：《中国医学工程》2025年第2期54-58,共5页China Medical Engineering

基　　金：河南省医学科技攻关项目(LHGJ202100221)。

摘　　要：目的 观察转铁蛋白受体单克隆抗体(TfR mAb)纳米载药系统辅助靶向治疗白血病的临床效果。方法 该次研究为前瞻性研究,选取2020年5月至2022年12月期间商丘市第一人民医院收治的白血病患者中随机抽取85例,分组方式为电脑随机分组法,将入组患者分别列为靶向组(42例)和联合组(43例),两组患者均接受靶向治疗,联合组采用TfR mAb纳米载药系统辅助靶向治疗,所有患者开展为期1年随访,比较两组患者的近期疗效及短期预后情况。结果 在不同治疗方案下,联合组治疗7 d、14 d、21 d后的人早幼粒白血病细胞(HL-60)凋亡率分别为(20.45±5.18)%、(23.36±5.47)%、(26.33±5.45)%,均高于靶向组[(18.45±3.23)%、(20.47±5.11)%、(23.44±5.23)%](P<0.05);联合组的总缓解率[86.05%(37/43)]高于靶向组[66.67%(28/42)](P<0.05);联合组的T淋巴细胞亚群CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)表达水平分别为(65.75±10.33)%、(70.24±10.31)%、(1.77±0.26),均高于靶向组[(60.35±10.44)%、(65.22±10.38)%、(1.24±0.72)](P<0.05);随访期间,联合组的中位无进展生存期(PFS)、中位总生存期(OS)分别为(9.36±1.45)个月、(10.41±2.25)个月,均高于靶向组[(8.41±1.25)个月、(9.33±1.72)个月](P<0.05);1年内病情复发率及死亡率分别为6.98%(3/43)、2.33%(1/43),均低于靶向组[28.57%(12/42)、21.43%(9/42)](P<0.05)。结论 TfR mAb纳米载药系统能增强白血病患者的靶向治疗效果,对促进HL-60细胞凋亡、改善机体免疫功能、延长患者生存周期并降低病情复发或死亡风险均有重要意义。【Objective】 To observe the clinical efficacy of TfR mAb nanocarrier system in assisting targeted therapy for leukemia.【Methods】 This study was a prospective study,in which 85 leukemia patients admitted to the First People's Hospital of Shangqiu City from May 2020 to December 2022 were randomly selected.The grouping method was computer randomization,and the enrolled patients were divided into a targeted group(42 cases) and a combination group(43 cases).Both groups of patients received targeted therapy,while the combination group received targeted therapy assisted by the TfR mAb nanocarrier system.All patients were followed up for one year,and the short-term efficacy and long-term prognosis of two groups of patients were compared.【Results】 Under different treatment regimens,the apoptosis rates of HL-60 cells in the combination group after 7 days,14 days,21 days of treatment were(20.45±5.18)%,(23.36±5.47)%,and(26.33±5.45)%,which were higher than the targeted group [(18.45±3.23)%,(20.47±5.11)%,and(23.44±5.23)%](P<0.05).The overall response rate of the combined group was 86.05%(37/43),higher than the targeted group [66.67%(28/42)](P<0.05).The expression levels of CD3~+,CD4~+,and CD4~+/CD8~+ in the combination group were(65.75±10.33)%,(70.24±10.31)%,and 1.77±0.26,higher than the targeted group [(60.35±10.44)%,(65.22±10.38)%,and 1.24±0.72](P<0.05).During the follow-up period,the median PFS and median OS of the combination group were 9.36±1.45 months and 10.41±2.25 months,higher than the targeted group(8.41±1.25 months and 9.33±1.72 months)(P<0.05).The recurrence rate and mortality rate within one year were 6.98%(3/43) and 2.33%(1/43),lower than the targeted group [28.57%(12/42) and 21.43%(9/42)](P<0.05).【Conclusion】 The TfR mAb nanocarrier system can enhance the targeted therapeutic effect of leukemia patients,and is of great significance in promoting HL-60 cell apoptosis,improving immune function,prolonging patient survival cycle,and reducing the risk of disease recurrence or death.

关 键 词：白血病 转铁蛋白受体单克隆抗体 纳米载药系统 细胞凋亡率 预后情况 

分 类 号：R733.7[医药卫生—肿瘤]